Simulations Plus (SLP) Q2 2026 earnings review
Operational Turnaround Masked by a Tax-Driven EPS Cut
Simulations Plus delivered a strong Q2, reversing Q1's revenue decline with an 8% top-line beat ($24.3M). The real story is the massive operational leverage: Adjusted EBITDA margin surged to 36% and gross margin expanded to 66%. The headline risk is a drastic cut to FY26 Adjusted EPS guidance (lowered to $0.75-$0.85 from $1.03-$1.10). However, this reduction is entirely driven by an expected tax rate spike to 23-25% (up from 12-14%), not a deterioration in business fundamentals. With backlog growing 18% and the macro environment improving, the operational trajectory is firmly accelerating.
🐂 Bull Case
The strategic reorganization from late FY25 is paying off. Gross profit margin accelerated to 66% from 59% a year ago, proving the company can drive significant profitability on modest top-line growth.
Management noted favorable market conditions, including stabilized pricing agreements, reduced tariff threats, and improving biotech funding. New FDA guidance on New Approach Methodologies (NAMs) is actively driving software and services demand.
🐻 Bear Case
The sudden jump in the expected effective tax rate from 12-14% to 23-25% severely impairs bottom-line earnings growth, forcing a ~25% cut to the midpoint of FY26 Adjusted EPS guidance.
While discovery and development software grew, total software growth was partially offset by an 'anticipated decline' in clinical operations software (Pro-ficiency), showing this segment has not yet stabilized.
⚖️ Verdict: 🟢
Bullish. Look past the EPS guidance cut—it is an accounting adjustment, not an operational failure. The business is accelerating, margins are expanding drastically, and macro headwinds are turning into tailwinds.
Key Themes
Macro and Regulatory Environment Reversing to Positive
After a grueling FY25 plagued by funding droughts and tariff fears, the macro environment is officially reversing. Management explicitly cited ongoing most-favored-nation pricing agreements, reduced tariff threats, and an improving funding environment. Crucially, the FDA's supplemental guidance on New Approach Methodologies (NAMs) is moving from a theoretical tailwind to a practical driver, pushing client activity higher across both software renewals and services bookings.
Operational Reorganization Yields Margin Acceleration
The company's transition to a functionally optimized structure is delivering tangible results. Gross margin accelerated sharply from 59% in 26Q2 to 66% in 26Q2. This flow-through allowed Adjusted EBITDA to grow 32% YoY to $8.7 million, outpacing the 8% revenue growth and yielding a highly profitable 36% margin for the quarter.
Services Backlog Accumulation
Services revenue grew 8% YoY to $9.7 million, but the leading indicator is the backlog. Bookings were strong during the quarter, resulting in an 18% sequential increase in total backlog to $24.0 million. This provides strong revenue visibility for the second half of FY26.
Tax Rate Spike Decimates EPS Profile
A reversing trend in the tax profile is the quarter's biggest negative. The expected effective tax rate for FY26 was drastically increased from 12-14% to 23-25%. This accounting shift forced a massive reduction in Adjusted EPS guidance down to $0.75-$0.85, obscuring the otherwise strong operational performance.
Clinical Ops Software Remains a Laggard
Software revenue growth (+9%) was impressive given it faced a headwind from the Pro-ficiency acquisition. Management cited an 'anticipated decline in clinical operations software' that offset strength in discovery and development solutions. Until this segment bottoms out, it will continue to suppress consolidated software growth rates.
Client Consolidations Pressuring Renewals
Despite favorable macro commentary, management noted that renewal rates continue to be impacted by client consolidations and site closures. This introduces friction into the recurring revenue base and contradicts the otherwise pristine narrative of a fully recovered biotech spending environment.
Other KPIs
Accelerating significantly. Gross profit jumped 23% YoY from $13.1 million in 25Q2, vastly outpacing the 8% revenue growth. The 700 basis point expansion in gross margin (to 66%) underscores improved utilization and pricing power.
Stable and highly liquid. Up from $32.4 million at the end of FY25. With zero long-term debt and strong free cash flow generation, the balance sheet is primed for further M&A or capital returns.
Guidance
Stable. The 0% to 4% full-year growth guidance implies a sequential deceleration in H2. Given H1 revenue of $42.7M, the midpoint implies H2 revenue of $37.8M. This means H2 will be slightly softer than H1, which is typical for the company's seasonality but warrants monitoring.
Stable. Reaffirmed from prior guidance. Given the 29% margin achieved in H1, the company is tracking comfortably toward the higher end of this range, provided there are no massive operational deleveraging events in H2.
Decelerating. Dramatically lowered from the prior $1.03-$1.10 range. This is the main blemish on the report, driven entirely by a sudden adjustment in the modeled effective tax rate from 12-14% to 23-25%.
Key Questions
Tax Rate Volatility
What were the specific triggers that caused the effective tax rate model to nearly double from 12-14% to 23-25% mid-year, and is 23-25% the new structural run-rate going forward?
Clinical Operations Bottom
Clinical operations software continues to act as a headwind to overall software growth. What are the specific leading indicators you are tracking to determine when the Pro-ficiency software business will finally stabilize and return to growth?
Capital Allocation Framework
With cash and short-term investments swelling to $41.8 million and no debt, how is management weighing the prioritization of tuck-in M&A versus initiating share repurchases, especially given the depressed GAAP earnings multiple?